Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Dis ; 216(suppl_1): S209-S216, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28838204

ABSTRACT

Background: We present an empirical economic cost analysis of the April 2016 switch from trivalent (tOPV) to bivalent (bOPV) oral polio vaccine at the national-level and 3 provinces (Bali, West Sumatera and Nusa Tenggara) for Indonesia's Expanded Program on Immunization. Methods: Data on the quantity and prices of resources used in the 4 World Health Organization guideline phases of the switch were collected at the national-level and in each of the sampled provinces, cities/districts, and health facilities. Costs were calculated as the sum of the value of resources reportedly used in each sampled unit by switch phase. Results: Estimated national-level costs were $46 791. Costs by health system level varied from $9062 to $34 256 at the province-level, from $4576 to $11 936 at the district-level , and from $3488 to $29 175 at the city-level. Estimated national costs ranged from $4 076 446 (Bali, minimum cost scenario) to $28 120 700 (West Sumatera, maximum cost scenario). Conclusions: Our findings suggest that the majority of tPOV to bOPV switch costs were borne at the subnational level. Considerable variation in reported costs among health system levels surveyed indicates a need for flexibility in budgeting for globally synchronized public health activities.


Subject(s)
Immunization Programs , Poliomyelitis/prevention & control , Poliovirus Vaccine, Oral , Costs and Cost Analysis , Drug Substitution , Humans , Immunization Programs/economics , Immunization Programs/statistics & numerical data , Immunization Programs/supply & distribution , Indonesia/epidemiology , Poliovirus Vaccine, Oral/administration & dosage , Poliovirus Vaccine, Oral/economics , Poliovirus Vaccine, Oral/supply & distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...